ArticleEMBO molecular medicine2020

HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies.

Lucía Gandullo-Sánchez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.